TRAVERE THERAPEUTICS, INC. Costs and Expenses
TRAVERE THERAPEUTICS, INC. (TVTX) reported Costs and Expenses of $165.63 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:CostsAndExpenses · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. costs and expenses for the quarter ending 2026-06-30 was $165.63M, a 30.32% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. costs and expenses for the quarter ending 2026-03-31 was $164.11M, a 31.92% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. costs and expenses for the quarter ending 2025-12-31 was $162.12M, a 19.62% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. costs and expenses for the quarter ending 2025-09-30 was $139.93M, a 17.54% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. costs and expenses for fiscal 2025 was $553.55M, a 0.62% decline from fiscal 2024.
- TRAVERE THERAPEUTICS, INC. costs and expenses for fiscal 2024 was $557.00M, a 4.43% increase from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. costs and expenses for fiscal 2023 was $533.38M, a 24.25% increase from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. costs and expenses for fiscal 2022 was $429.27M, a 29.59% increase from fiscal 2021.
| Period end | Costs and Expenses 3 month | Costs and Expenses 3 month as first filed | Costs and Expenses 6 month | Costs and Expenses 6 month as first filed | Costs and Expenses 9 month | Costs and Expenses 9 month as first filed | Costs and Expenses 12 month | Costs and Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $165.63M 10-Q · filed 2026-08-04 | $329.74M 10-Q · filed 2026-08-04 | $491.86M derived: sum of 3 quarters · filed 2026-08-04 | $631.79M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $164.11M 10-Q · filed 2026-05-04 | $326.23M derived: sum of 2 quarters · filed 2026-05-04 | $466.16M derived: sum of 3 quarters · filed 2026-05-04 | $593.26M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $162.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $302.05M derived: sum of 2 quarters · filed 2026-02-19 | $429.14M derived: sum of 3 quarters · filed 2026-08-04 | $553.55M 10-K · filed 2026-02-19 | ||||
| 2025-09-30 | $139.93M 10-Q · filed 2025-10-30 | $267.03M derived: sum of 2 quarters · filed 2026-08-04 | $391.44M 10-Q · filed 2025-10-30 | $526.96M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $127.10M 10-Q · filed 2026-08-04 | $251.51M 10-Q · filed 2026-08-04 | $387.03M derived: sum of 3 quarters · filed 2026-08-04 | $506.08M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $124.41M 10-Q · filed 2026-05-04 | $259.93M derived: sum of 2 quarters · filed 2026-05-04 | $378.98M derived: sum of 3 quarters · filed 2026-05-04 | $500.80M derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $135.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $254.57M derived: sum of 2 quarters · filed 2026-02-19 | $376.39M derived: sum of 3 quarters · filed 2026-02-19 | $557.00M 10-K · filed 2026-02-19 | ||||
| 2024-09-30 | $119.05M 10-Q · filed 2025-10-30 | $240.87M derived: sum of 2 quarters · filed 2025-10-30 | $421.48M 10-Q · filed 2025-10-30 | $560.77M derived: sum of 4 quarters · filed 2025-10-30 | ||||
| 2024-06-30 | $121.82M 10-Q · filed 2025-08-06 | $302.43M 10-Q · filed 2025-08-06 | $441.72M derived: sum of 3 quarters · filed 2025-08-06 | $571.40M derived: sum of 4 quarters · filed 2025-08-06 | ||||
| 2024-03-31 | $180.61M 10-Q · filed 2025-05-01 | $319.90M derived: sum of 2 quarters · filed 2025-05-01 | $449.58M derived: sum of 3 quarters · filed 2025-05-01 | $585.73M derived: sum of 4 quarters · filed 2025-05-01 | ||||
| 2023-12-31 | $139.29M 10-K · filed 2024-02-20 | $268.97M derived: sum of 2 quarters · filed 2024-10-31 | $405.12M derived: sum of 3 quarters · filed 2024-10-31 | $533.38M 10-K · filed 2026-02-19 | ||||
| 2023-09-30 | $129.68M 10-Q · filed 2024-10-31 | $265.83M derived: sum of 2 quarters · filed 2024-10-31 | $394.08M 10-Q · filed 2024-10-31 | $510.13M derived: sum of 4 quarters · filed 2024-10-31 | ||||
| 2023-06-30 | $136.15M 10-Q · filed 2024-08-01 | $147.28M 10-Q · filed 2023-08-03 | $264.40M 10-Q · filed 2024-08-01 | $291.32M 10-Q · filed 2023-08-03 | $380.44M derived: sum of 3 quarters · filed 2024-08-01 | $491.12M derived: sum of 4 quarters · filed 2024-08-01 | ||
| 2023-03-31 | $128.26M 10-Q · filed 2024-05-06 | $144.04M 10-Q · filed 2023-05-04 | $244.30M derived: sum of 2 quarters · filed 2024-05-06 | $354.98M derived: sum of 3 quarters · filed 2024-05-06 | $462.14M derived: sum of 4 quarters · filed 2024-05-06 | |||
| 2022-12-31 | $116.04M 10-K · filed 2024-02-20 | $226.72M derived: sum of 2 quarters · filed 2024-02-20 | $333.88M derived: sum of 3 quarters · filed 2024-02-20 | $429.27M 10-K · filed 2025-02-21 | $478.58M 10-K · filed 2023-02-23 | |||
| 2022-09-30 | $110.68M 10-K · filed 2024-02-20 | $121.63M 10-Q · filed 2022-10-27 | $217.84M derived: sum of 2 quarters · filed 2024-02-20 | $313.23M 10-Q · filed 2023-11-07 | $355.87M 10-Q · filed 2022-10-27 | $359.68M derived: sum of 4 quarters · filed 2024-02-20 | ||
| 2022-06-30 | $107.16M 10-K · filed 2024-02-20 | $119.62M 10-Q · filed 2022-08-04 | $234.24M 10-Q · filed 2023-08-03 | $249.00M derived: sum of 3 quarters · filed 2024-02-20 | $348.93M derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2022-03-31 | $95.39M 10-K · filed 2024-02-20 | $114.62M 10-Q · filed 2022-05-05 | $141.84M derived: sum of 2 quarters · filed 2024-02-20 | $241.77M derived: sum of 3 quarters · filed 2024-02-20 | $331.70M derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2021-12-31 | $46.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $146.37M derived: sum of 2 quarters · filed 2024-02-20 | $236.31M derived: sum of 3 quarters · filed 2024-02-20 | $331.26M 10-K · filed 2024-02-20 | $389.25M 10-K · filed 2022-02-24 | |||
| 2021-09-30 | $99.93M 10-Q · filed 2022-10-27 | $189.86M derived: sum of 2 quarters · filed 2022-10-27 | $284.82M 10-Q · filed 2022-10-27 | $454.35M derived: sum of 4 quarters · filed 2022-10-27 | ||||
| 2021-06-30 | $89.93M 10-Q · filed 2022-08-04 | $184.89M 10-Q · filed 2022-08-04 | $354.42M derived: sum of 3 quarters · filed 2022-08-04 | $425.00M derived: sum of 4 quarters · filed 2022-08-04 | ||||
| 2021-03-31 | $94.96M 10-Q · filed 2022-05-05 | $264.49M derived: sum of 2 quarters · filed 2022-05-05 | $335.06M derived: sum of 3 quarters · filed 2022-05-05 | $406.60M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $169.53M 10-K · filed 2021-03-01 | $240.11M derived: sum of 2 quarters · filed 2021-10-29 | $311.65M derived: sum of 3 quarters · filed 2021-10-29 | $374.48M 10-K · filed 2023-02-23 | ||||
| 2020-09-30 | $70.57M 10-Q · filed 2021-10-29 | $142.12M derived: sum of 2 quarters · filed 2021-10-29 | $204.95M 10-Q · filed 2021-10-29 | $279.81M derived: sum of 4 quarters · filed 2021-10-29 | ||||
| 2020-06-30 | $71.54M 10-Q · filed 2021-07-29 | $134.38M 10-Q · filed 2021-07-29 | $209.23M derived: sum of 3 quarters · filed 2021-07-29 | $288.04M derived: sum of 4 quarters · filed 2021-07-29 | ||||
| 2020-03-31 | $62.84M 10-Q · filed 2021-05-06 | $1.37M 10-Q · filed 2020-05-11 | $137.69M derived: sum of 2 quarters · filed 2021-05-06 | $216.50M derived: sum of 3 quarters · filed 2021-05-06 | $297.74M derived: sum of 4 quarters · filed 2021-05-06 | |||
| 2019-12-31 | $74.86M 10-K · filed 2021-03-01 | $153.66M derived: sum of 2 quarters · filed 2021-03-01 | $234.90M derived: sum of 3 quarters · filed 2021-03-01 | $312.70M 10-K · filed 2022-02-24 | ||||
| 2019-09-30 | $78.81M 10-K · filed 2021-03-01 | $160.05M derived: sum of 2 quarters · filed 2021-03-01 | $237.84M 10-Q · filed 2020-11-05 | $286.60M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $81.24M 10-K · filed 2021-03-01 | $159.03M 10-Q · filed 2020-07-31 | $207.79M derived: sum of 3 quarters · filed 2021-03-01 | $284.08M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $77.80M 10-K · filed 2021-03-01 | $126.55M derived: sum of 2 quarters · filed 2021-03-01 | $202.84M derived: sum of 3 quarters · filed 2021-03-01 | $265.74M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $48.76M 10-K · filed 2020-02-24 | $125.05M derived: sum of 2 quarters · filed 2020-02-24 | $187.94M derived: sum of 3 quarters · filed 2020-02-24 | $244.29M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $76.29M 10-K · filed 2020-02-24 | $139.19M derived: sum of 2 quarters · filed 2020-02-24 | $195.53M derived: sum of 3 quarters · filed 2020-02-24 | |||||
| 2018-06-30 | $62.90M 10-K · filed 2020-02-24 | $119.24M derived: sum of 2 quarters · filed 2020-02-24 | ||||||
| 2018-03-31 | $56.34M 10-K · filed 2020-02-24 | |||||||
| 2017-12-31 | $208.73M 10-K · filed 2020-02-24 | |||||||
| 2012-11-30 | $3.66K 10-Q · filed 2013-03-06 | $7.16K derived: sum of 2 quarters · filed 2013-03-06 | $10.67K 10-Q · filed 2013-03-06 | |||||
| 2012-08-31 | $3.50K 10-Q · filed 2012-10-10 | $7.01K 10-Q · filed 2012-10-10 | ||||||
| 2012-05-31 | $3.51K 10-Q · filed 2012-08-08 | |||||||
| 2012-02-29 | $14.82K 10-K · filed 2012-05-24 | |||||||
| 2011-11-30 | $3.52K 10-Q · filed 2013-03-06 | $7.04K derived: sum of 2 quarters · filed 2013-03-06 | $10.57K 10-Q · filed 2013-03-06 | $14.65K derived: sum of 4 quarters · filed 2013-03-06 | ||||
| 2011-08-31 | $3.52K 10-Q · filed 2012-10-10 | $7.05K 10-Q · filed 2012-10-10 | $11.13K derived: sum of 3 quarters · filed 2012-10-10 | $16.80K derived: sum of 4 quarters · filed 2012-10-10 | ||||
| 2011-05-31 | $3.52K 10-Q · filed 2012-08-08 | $7.60K derived: sum of 2 quarters · filed 2012-08-08 | $13.28K derived: sum of 3 quarters · filed 2012-08-08 | $19.90K derived: sum of 4 quarters · filed 2012-08-08 | ||||
| 2011-02-28 | $4.08K derived: 10-K 12 month − 10-Q 9 month · filed 2012-05-24 | $9.75K derived: sum of 2 quarters · filed 2012-05-24 | $16.38K derived: sum of 3 quarters · filed 2012-06-06 | $23.02K 10-K · filed 2012-05-24 | ||||
| 2010-11-30 | $5.67K 10-Q · filed 2012-01-11 | $12.30K derived: sum of 2 quarters · filed 2012-06-06 | $18.94K 10-Q · filed 2012-01-11 | |||||
| 2010-08-31 | $6.63K 10-Q/A · filed 2012-06-06 | $13.27K 10-Q/A · filed 2012-06-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |